BE620906A - - Google Patents
Info
- Publication number
- BE620906A BE620906A BE620906DA BE620906A BE 620906 A BE620906 A BE 620906A BE 620906D A BE620906D A BE 620906DA BE 620906 A BE620906 A BE 620906A
- Authority
- BE
- Belgium
- Prior art keywords
- heparin
- process according
- glycolic
- sep
- activity
- Prior art date
Links
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 46
- 229960002897 Heparin Drugs 0.000 claims description 41
- 229920000669 heparin Polymers 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 238000006722 reduction reaction Methods 0.000 claims description 12
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 11
- 238000010504 bond cleavage reaction Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- KHIWWQKSHDUIBK-UHFFFAOYSA-M AC1L4ZKD Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 claims description 8
- 125000003172 aldehyde group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 230000002402 anti-lipaemic Effects 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000002329 infrared spectrum Methods 0.000 claims description 3
- 239000003638 reducing agent Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000003247 decreasing Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 229910052987 metal hydride Inorganic materials 0.000 claims description 2
- 150000004681 metal hydrides Chemical class 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical group [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 alkali metal periodate Chemical class 0.000 claims 2
- 235000006696 Catha edulis Nutrition 0.000 claims 1
- 240000007681 Catha edulis Species 0.000 claims 1
- 206010013647 Drowning Diseases 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 150000003385 sodium Chemical group 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 40
- 239000000463 material Substances 0.000 description 11
- 210000002381 Plasma Anatomy 0.000 description 7
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 206010062060 Hyperlipidaemia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 230000002429 anti-coagulation Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000002337 glycosamines Chemical group 0.000 description 3
- 230000003458 metachromatic Effects 0.000 description 3
- 150000004044 tetrasaccharides Chemical group 0.000 description 3
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 2
- 206010009802 Coagulopathy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229960002442 Glucosamine Drugs 0.000 description 2
- 229940097043 Glucuronic Acid Drugs 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 1
- JPIJQSOTBSSVTP-PWNYCUMCSA-N D-erythronic acid Chemical compound OC[C@@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-PWNYCUMCSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- FJVZDOGVDJCCCR-UHFFFAOYSA-M Potassium periodate Chemical compound [K+].[O-]I(=O)(=O)=O FJVZDOGVDJCCCR-UHFFFAOYSA-M 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 150000001339 alkali metal compounds Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CROBTXVXNQNKKO-UHFFFAOYSA-N borohydride Chemical compound [BH4-] CROBTXVXNQNKKO-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- KLDBIFITUCWVCC-UHFFFAOYSA-N diborane(6) Chemical compound [H]B1([H])[H]B([H])([H])[H]1 KLDBIFITUCWVCC-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001667 episodic Effects 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE620906A true BE620906A (zh) |
Family
ID=194152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE620906D BE620906A (zh) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE620906A (zh) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0287477A2 (fr) | 1987-04-16 | 1988-10-19 | Sanofi | Héparines de bas poids moléculaire à structure régulière leur préparation et leurs applications biologiques |
| EP0577756A1 (en) * | 1991-03-29 | 1994-01-12 | Glycomed Incorporated | New non-anticoagulant heparin derivatives |
| EP0582330A1 (en) * | 1992-07-31 | 1994-02-09 | Crinos Industria Farmacobiologica S.p.A. | Use of polysaccharides for treating acute peripheral neuropathies |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US9351992B2 (en) | 2007-11-02 | 2016-05-31 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| US9387256B2 (en) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
| US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
-
0
- BE BE620906D patent/BE620906A/fr unknown
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0287477A2 (fr) | 1987-04-16 | 1988-10-19 | Sanofi | Héparines de bas poids moléculaire à structure régulière leur préparation et leurs applications biologiques |
| FR2614026A1 (fr) * | 1987-04-16 | 1988-10-21 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| EP0287477A3 (en) * | 1987-04-16 | 1989-07-26 | Sanofi | Low molecular weight heparins with a regular structure, their preparation and biological uses |
| EP0577756A1 (en) * | 1991-03-29 | 1994-01-12 | Glycomed Incorporated | New non-anticoagulant heparin derivatives |
| EP0577756A4 (zh) * | 1991-03-29 | 1994-02-09 | Glycomed, Incorporated | |
| EP0582330A1 (en) * | 1992-07-31 | 1994-02-09 | Crinos Industria Farmacobiologica S.p.A. | Use of polysaccharides for treating acute peripheral neuropathies |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US9212233B2 (en) | 2007-11-02 | 2015-12-15 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US9351992B2 (en) | 2007-11-02 | 2016-05-31 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| US9358252B2 (en) | 2007-11-02 | 2016-06-07 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US9387256B2 (en) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
| US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0116801B1 (fr) | Héparine dépolymérisée et supersulfatée, procédé pour sa préparation et compositions pharmaceutiques en contenant | |
| EP0325872B1 (fr) | Procédé de préparation enzymatique d'oligodextranes utiles dans la fabrication de substituts du sucre, et nouveaux oligodextranes | |
| EP0037319B2 (fr) | Mucopolysaccharides possédant des propriétés biologiques, leur préparation et leur application en tant que médicaments | |
| CA1052307A (fr) | Procede d'extraction et de traitement de glycoproteines, de mucopolysaccharides et de substances qui les accompagnent | |
| CH633583A5 (fr) | Procede de determination de l'amylase. | |
| FR2474508A1 (fr) | Procede pour obtenir des heparines de bas poids moleculaire ayant des proprietes pharmacologiques remarquables et produit ainsi obtenu | |
| BG97637A (bg) | Преработване на дрождеви отпадъци и полученият врезултат на това продукт | |
| EP0124439A2 (fr) | Procédé de modification des pectines de betterave, produits obtenus et leurs applications | |
| FR2470148A1 (fr) | Procede de preparation de fibres solubles de collagene | |
| DE2433883A1 (de) | Geschuetztes polypeptid, im wesentlichen nicht immunogene, enzymisch aktive substanz sowie verfahren zum weitgehenden unterdruekken der immunogenizitaet eines polypeptids | |
| FR2626145A1 (fr) | Procede d'elimination de composes steroidiques contenus dans une substance d'origine biologique | |
| EP0542914A1 (en) | Improved diagnostic and therapeutic compositions | |
| BE620906A (zh) | ||
| Saha et al. | Aqueous biphasic systems: A robust platform for green extraction of biomolecules | |
| JP2003527434A (ja) | 虚血／再潅流又は酸化的ストレスに起因する損傷の治療に適した組成物 | |
| EP0568618B1 (fr) | Produit complexe de polyose et d'acide gras a forte teneur en acide gras, utilisation comme agent emulsionnant ou hydratant et composition emulsionnante ou hydratante en contenant | |
| Manson et al. | The alkali-induced elimination of phosphate from β-casein | |
| EP1489135A1 (en) | Use of secoiridoids, preferably oleuropein, for cross-linking biopolymers | |
| CA2223740A1 (fr) | Utilisation des sophorolipides en tant qu'agent stimulateur du metabolisme des fibroblastes dermiques | |
| EP0286761B1 (fr) | Procédé enzymatique de traitement de gommes xanthanes en vue d'ameliorer la filtrabilté de leurs solutions aqueuses | |
| Lina et al. | Subchronic oral toxicity studies with γ-cyclodextrin in rats | |
| JP4119482B2 (ja) | 親水性置換基としてカルボキシル低級アルキル基および疎水性置換基を有するキチン誘導体、当該キチン誘導体からなる高分子ミセル型担体およびそのミセル様水性組成物 | |
| FR2473887A1 (fr) | Nouvelle utilisation des precurseurs biochimiques des glucosamino-glycanes et compositions pharmaceutiques et cosmetiques respectives | |
| JPH0441997B2 (zh) | ||
| JPH06247860A (ja) | グアーガム酵素分解物を有効成分とする鉄吸収促進剤 |